Free shipping on all orders over $ 500

LY2334737

Cat. No. M8960
LY2334737 Structure
Size Price Availability
5mg USD 270 4-7 Days
10mg USD 420 4-7 Days
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

LY2334737 is an orally available valproic acid ester of gemcitabine, a broad-spectrum antimetabolite with antineoplastic activity. Gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate and triphosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually the induction of apoptosis.

In vivo: Oral treatment of xenograft models with 3.2 mg/kg LY2334737 once a day for 21 days showed greater tumor growth inhibition of CES2 transfectant than the mock transfectant (P ≤ 0.001).

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 389.39
Formula C17H25F2N3O5
CAS Number 892128-60-8
Purity >98%
Solubility DMSO 10 mM
Storage at -20°C
References

Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells.
Pratt SE, et al. Clin Cancer Res. 2013 Mar 1;19(5):1159-68. PMID: 23325581.

Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Francia G, et al. Mol Cancer Ther. 2012 Mar;11(3):680-9. PMID: 22188817.

Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Koolen SL, et al. Clin Cancer Res. 2011 Sep 15;17(18):6071-82. PMID: 21753156.

Related Products
DTT

Dithiothreitol (DTT) is the common name for a small-molecule redox reagent known as Cleland's reagent; as a reducing or "deprotecting" agent for thiolated DNA.

SAR7334

SAR7334 is a novel, highly potent and bioavailable inhibitor of TRPC6 channels.

FICZ

FICZ is a potent aryl hydrogen receptor (AhR) agonist.

NAD+

NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.

STING-Inducer-1

STING-Inducer-1 (ML RR-S2 CDA) is an inducer of STING (stimulator of interferon genes).

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: LY2334737 supplier, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.